Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Oncothyreon ( ONTY)

Another cancer immunotherapy, or "cancer vaccine" stock hoping to replicate the success of Dendreon while sidestepping Provenge's problems. Oncothyreon and its partner Merck KGaA are gearing up to perform an interim analysis on a phase III study of their Stimuvax immunotherapy in non-small cell lung cancer patients. Trading volume and volatility in Oncothyreon have increased dramatically in recent months as investors focus hard on this interim analysis, which is expected in the first quarter of next year.

Year to date performance: + 107%

Performance since June 30: -26%

Three hedge funds -- Biotechnology Value Fund (BVF), Orbimed Advisors and Black Horse Capital -- added significant new Oncothyreon positions in the second quarter. Each firm owned well over 1 million shares of the company as of June 30. Antipodean Advisors bought 1.6 million shares during the quarter to bring its total holding to 2.3 million shares.

Selling hedge funds included RA Capital, which liquidated its 236,000-share position in Oncothyreon during the second quarter. Straus Capital Management and Highland Capital Management also were sellers.

If you liked this article you might like

Cancer Drug Stocks: The Winners and Losers From ASCO 2016

5 Stocks Under $10 Set to Soar

8 Stocks Under $10 Making Big Moves Higher

Yellen's Hawkish Claws Rattle Market

Yellen's Hawkish Claws Rattle Market

4 Stocks Under $10 to Trade for Big Breakouts